Barr I G, Hurt A C, Deed N, Iannello P, Tomasov C, Komadina N
WHO Collaborating Centre for Reference and Research on Influenza, 45 Poplar Road, Parkville, Melbourne 3052, Australia.
Antiviral Res. 2007 Aug;75(2):173-6. doi: 10.1016/j.antiviral.2007.01.006. Epub 2007 Feb 15.
The adamantanes (amantadine and rimantadine) were the first antivirals licensed for use against influenza A viruses and have been used in some countries to control seasonal influenza. While increasing resistance of A(H3) viruses to this class of drug has been reported in recent years, only low levels of resistance were seen with A(H1) viruses until the 2005-2006 influenza season in the USA. In this study we analysed 101 human influenza A viruses isolated in 2006 that were referred to the WHO Collaborating Centre for Reference and Research in Melbourne, from Australia and the surrounding regions, for evidence of resistance to adamantanes. We found that whereas previously A(H1) resistant viruses were rare, 21.8% of the 2006 viruses had a resistant genotype. By comparison, 58.6% of influenza A(H3) viruses isolated in 2006 that were tested at the Centre, had a resistant genotype.
金刚烷类药物（金刚烷胺和金刚乙胺）是首批获准用于抗甲型流感病毒的抗病毒药物，在一些国家已被用于控制季节性流感。尽管近年来有报道称甲型（H3）病毒对这类药物的耐药性不断增加，但在美国，直到2005 - 2006年流感季节，甲型（H1）病毒的耐药水平一直较低。在本研究中，我们分析了2006年分离的101株甲型流感病毒，这些病毒来自澳大利亚及周边地区，并被送往墨尔本的世界卫生组织参比和研究合作中心，以检测其对金刚烷类药物的耐药证据。我们发现，虽然此前甲型（H1）耐药病毒很少见，但2006年的病毒中有21.8%具有耐药基因型。相比之下，该中心检测的2006年分离的甲型（H3）流感病毒中有58.6%具有耐药基因型。
